AtriCure Inc
ATRC
Company Profile
Business description
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
Contact
7555 Innovation Way
MasonOH45040
USAT: +1 513 755-4100
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
1,200
Stocks News & Analysis
stocks
Megatrend Investing 2025 and beyond: ASX players to capitalise on the clean energy transition
Find out how you can benefit from global megatrends.
stocks
DeepSeek revelation hits US chip stocks, ASX data centres and uranium
Shockwaves from Monday's AI stock panic in the US were largely confined to two ASX industries.
video
What does a weak Aussie dollar mean for investors?
Morningstar Investment Management's Chief Investment Officer for Asia Pacific weighs in on the weak Aussie dollar and what this could mean for investors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,789.70 | 43.80 | 0.50% |
| CAC 40 | 7,950.17 | 8.53 | 0.11% |
| DAX 40 | 21,732.05 | 4.85 | 0.02% |
| Dow JONES (US) | 44,544.66 | 337.47 | -0.75% |
| FTSE 100 | 8,673.96 | 27.08 | 0.31% |
| HKSE | 20,225.11 | 27.34 | 0.14% |
| NASDAQ | 19,627.44 | 54.31 | -0.28% |
| Nikkei 225 | 39,572.49 | 58.52 | 0.15% |
| NZX 50 Index | 12,995.01 | 66.63 | 0.52% |
| S&P 500 | 6,040.53 | 30.64 | -0.50% |
| S&P/ASX 200 | 8,532.30 | 38.60 | 0.45% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |